• Lakewood-Amedex Biotherapeutics shifted its stock listing to the Nasdaq Capital Market under ticker LABT on April 23, 2026.
• The listing followed a $7.5 million private placement of Series C Convertible Preferred Stock, aimed at supporting clinical development.
• Earlier preferred stock and convertible notes converted into common stock in connection with the Nasdaq listing, simplifying the capital structure.
• A Sept. 18 registration statement covered up to 4,512,400 common shares issuable from remaining Series C conversions, enabling staged sales.
• Shareholders vote Sept. 22 on raising authorized common shares to 100 million, with reverse-split authority up to 1-for-20 if needed for Nasdaq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609210802PR_NEWS_USPR_____NY52203) on September 21, 2026, and is solely responsible for the information contained therein.